C-Stem™ The scalable technology platform for cell therapy.
C-Stem™, a proprietary GMP-compliant technology platform designed to solve the scalability and quality issues facing the efficient mass production of next-generation cell therapies.
C-Stem™, a proprietary GMP-compliant technology platform designed to solve the scalability and quality issues facing the efficient mass production of next-generation cell therapies.
C-Stem™ is the world’s first high-throughput 3D cell culture platform that protects stem cells within biomimetic capsules, enabling industrial-scale production without compromising on cell quality or genomic integrity.
Learn more about C-Stem™ through Biomaterials publicationWe developed our process in parallel with our science to avoid the ‘innovation trap’ that stalls most cell therapies.
Traditional 2D and 3D bioreactor methods subject delicate stem cells to shear stress leading to low yields.
C-Stem™ changes the environment,
not the biology.
Our plug-and-play GMPc closed loop model has proven to be compatible with existing partners’ innovation. We have a suite of GMPc models to ensure efficiency at all stages in development, from R&D through to commercialisation.
With C-Stem™, we focus on optimizing both yield and quality through all stages of amplification and differentiation and from R&D to final product.
Introducing the dedicated Amazonia microscope which allows in-process QC, standardized imaging analysis, and can be installed in GMP suites.
A microscope developed in-house powerful enough to monitor amplification and characterization of cells to ensure therapies are proven safe and effective.
Whether you are in early stage R&D or preparing for clinical trials, our hubs in Bordeaux and Boston are ready to integrate C-Stem™ into your workflow.
A highly-scalable, safe
and cost-efficient
cell therapy.